On November 6, 2025, Lantheus announced a leadership transition with CEO Brian Markison retiring effective December 31, 2025, and Mary Anne Heino appointed as Executive Chair and Interim CEO. The company reported third-quarter 2025 financial results, including a revenue of $384 million and a decrease in net income, while also highlighting strategic initiatives such as the acquisition of Life Molecular Imaging and the advancement of its radiopharmaceutical pipeline.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.